Skip to content
Subscriber Only

Teva Said to Take Acquisition Bid Directly to Mylan Holders

Updated on

Teva Pharmaceutical Industries Ltd., whose $40.1 billion takeover offer for Mylan NV was rejected, is meeting with key shareholders of the target company to win their support, people with knowledge of the matter said.

Some of the meetings have been scheduled for this week in New York, according to one of the people, who asked not to be identified because they’re not authorized to speak publicly on the matter. The goal is to convince shareholders that Mylan would be better off in Teva’s control, the people said.